Alison Bryant

Biography for Alison Bryant

Alison Bryant began at FierceVaccines in 2012. She has covered local politics, growth and development and breaking news in Maryland and Vermont. Her work has been published in The Washington Post, The Burlington Free Press and The Gazette. In her free time, Bryant enjoys reading, creative writing and yoga. She's based in Washington, D.C. and can be reached at Follow @AlisonBFierce on Twitter.

Articles by Alison Bryant

Immunotherapy bats out Type 1 diabetes in mice

A new study completed by researchers at the University of North Carolina demonstrated injecting non-obese diabetic mice with nondepleting antibodies rapidly reversed Type 1 diabetes.

Brigham and Women's aims to stomp out lethal pneumonia

Researchers at the Boston hospital say they discovered a new vaccine candidate that aims to fight infections, like Pseudomonas aeruginosa.

Indonesia to produce bird flu vaccine in 2013

In an effort to cut costs, Indonesia's PT Bio Farma will start producing a vaccine for the bird flu virus by 2013.

ASU's Biodesign Institute enhances salmonella vaccine safety

A few new Salmonella Typhi vaccines use live attenuated strains of the bacteria, but such methods can mean the salmonella is shed into the environment through excrement. Researchers at Arizona State University's Biodesign Institute have been researching ways to detect S. Typhi--the cause of typhoid fever--in feces after use of the vaccine.

In $69M IPO bid, GlobeImmune spotlights therapeutic vaccines

GlobeImmune has detailed plans for a $69 million IPO, aiming to rally public investors to back development of its therapeutic vaccines.

FDA gives Argos green light for kidney cancer immunotherapy

The FDA approved Argos Therapeutics' a revised Special Protocol Assessment (SPA) for its Phase III clinical study of AGS-003 for the treatment of metastatic renal cell carcinoma, or kidney cancer.

Children in Philippines receive rotavirus vaccination

About 700,000 children in the Philippines will receive a rotavirus vaccination, thanks to a national immunization program for children.

Soligenix, Infectious Disease Research Institute partner to combat anthrax

Soligenix, a Princeton, NJ-based biopharmaceutical company, will partner with the Infectious Disease Research Institute of Seattle, to develop biodefense vaccines.

Group tackles dengue vaccine pricing

Production of a dengue vaccine could cost mere pocket change, according to an economic analysis completed by the Dengue Vaccine Initiative. Producing a tetravalent dengue vaccine could cost as little as 20 cents per dose, with an annual production level of 60 million doses packaged in 10-dose vials.

Vaccine triggers attack on nicotine in mice

An experimental vaccine could smother a smoker's addiction to nicotine. Researchers at Weill Cornell Medical College developed and successfully tested in mice a vaccine to treat such dependence.